Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Aprocitentan (Primary)
- Indications Resistant hypertension
- Focus Registrational; Therapeutic Use
- Acronyms PRECISION
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 05 Sep 2024 According to an Idorsia Pharmaceuticals Media Release, A biomarker analysis from this PRECISION study will be presented as poster presentation by Martine Clozel, Poster session 2, salon D, on Sep 6 and as oral presentation by Martine Clozel, Session 12 A, Anti-hypertensive drugs, on Sep 6 at at the American Heart Association (AHA) Hypertension Scientific Sessions 2024, taking place in Chicago, Illinois, September 5-8, 2024.
- 01 Jul 2024 According to an Idorsia Pharmaceuticals Media Release, European Commission (EC) has approved JERAYGO (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products. Company will now work to expand marketing authorization by also applying for JERAYGO approval in the UK, Canada, and Switzerland.
- 03 Jun 2024 Results assessing the % of subjects with controlled blood pressure according to hypertension guidelines at different timepoints during the study, presented at the 33rd European meeting on hypertension and cardiovascular protection.